

Tecelra® Cell Therapy Treatment Centers

ETS Program Reference Guide

Emerging Therapy Solutions® (ETS) helps reinsurance and stop-loss payers, health plans, HMOs, and self-funded employers, along with third-party administrators and brokers, manage the risk associated with high-cost therapies for rare and complex conditions.

Programs listed here are qualified treatment centers (QTCs) for which ETS either may have contracted rates in place or may have access to rates through single case agreements for **Tecelra®** (afamitresgene autoleucel; afami-cel) which is approved to treat **Synovial Sarcoma**.

For assistance with your member referral or for more information, contact ETS at <u>clientservices@emergingtherapies.com</u> or 877-445-4822.

▼ Denotes facilities that currently have cellular therapy rates in place with ETS.

State	City	Program Listing
California	Duarte	City of Hope
	Loma Linda	Loma Linda University Medical Center
	Stanford	Stanford Hospitals and Clinics ▼
Florida	Tampa	H. Lee Moffitt Cancer Center ▼
Illinois	Chicago	Northwestern Memorial Hospital
Michigan	Ann Arbor	University of Michigan Medical Center▼
Missouri	St. Louis	Barnes-Jewish Hospital ▼
New York	New York	Memorial Sloan-Kettering Cancer Center
North Carolina	Durham	Duke University Hospital
Ohio	Columbus	James Cancer Hospital
Oregon	Portland	Oregon Health & Science University
Tennessee	Nashville	Vanderbilt University Medical Center
Texas	Houston	MD Anderson Cancer Center

© 2025 Emerging Therapy Solutions, Inc. All Rights Reserved. AP-11357. ETS is a trademark of Emerging Therapy Solutions, Inc. All other trademarks referenced herein are the property of their respective owners. The information provided here is believed to be accurate as of the listed document production date and is based on information currently available to us. Because facility and program changes may occur, please confirm details with our ETS clinical consultants at 877-445-4822 or clientservices@emergingtherapies.com. Please note that coverage for any indicated services is subject to applicable plan documents. 7/18/2025